Replies to post #153545 on Biotech Values

[caravon]

One more thing.

EXEL's statement that their drug efficacy is not C-MET status sensitive is just irresponsible since the management has no clinical data to substantiate their claim.

Unfortunately, here I see lots of commonalities with ARQL's management incompetence doing the same unsubstantiated claims until the Marquee's failure.

Note that ARQL's NSCLC Ph2 c-MET analyses are very unreliable since c-MET testing was done for only third of all pts and it is very questionable that c-MET testing (samples selection) was in any way randomized to properly reflect the general NSCLC Ph2 pts population.